Lung adenocarcinoma bio-immunotherapy program requires a comprehensive and individualized treatment plan by a specialist based on the state of the organism, lung cancer pathology and stage. Part of the treatment should be targeted therapy and part of the treatment should be PD-1 immunotherapy.
1. Targeted therapy: applied to patients with adenocarcinoma in non-small cell lung cancer, commonly used drugs include gefitinib, erlotinib, daclotinib, afatinib and ositinib.
2. Immunotherapy: killing cancer cells by enhancing the body’s immune response, such as PD-1 or PD-L1 inhibitors, which enables a few advanced patients to obtain long-term survival, mainly including nabumab and pembrolizumab.
Lung adenocarcinoma bio-immunotherapy needs to be guided by specialists and should not be used without authorization. If there is any discomfort, consult the doctor in time for clear diagnosis and treatment so as to avoid delaying the condition.